[go: up one dir, main page]

NO20071853L - Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose. - Google Patents

Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.

Info

Publication number
NO20071853L
NO20071853L NO20071853A NO20071853A NO20071853L NO 20071853 L NO20071853 L NO 20071853L NO 20071853 A NO20071853 A NO 20071853A NO 20071853 A NO20071853 A NO 20071853A NO 20071853 L NO20071853 L NO 20071853L
Authority
NO
Norway
Prior art keywords
polydextrose
phase
uniform
polymer
pharmaceutical composition
Prior art date
Application number
NO20071853A
Other languages
English (en)
Inventor
Thierry Breul
Michel Bedos
Dos Santos Isabel Riberio
Stephen Byard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20071853L publication Critical patent/NO20071853L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives et fast, farmasøytisk preparat omfattende en fast dispersjon omfattende minst en aktiv bestanddel og en farmasøytisk akseptabel polymermatriks. Spesielt beskriver at den farmasøytisk akseptabel polymermatriks omfatter en blanding av (i) polydekstrose, i form av en kontinuerlig polydekstrosefase, for å favorisere desintegrering av preparater i et vandig medium, og (ii) minst en polymer forskjellig fra polydekstrose, i form av en kontinuerlig fase, hvorved polydekstrosen er i en konsentrasjon på minst 20 vekt-% og den minst ene polymer forskjellig fra polydekstrose er i en konsentrasjon på minst 20 vekt-%, beregnet på den totale vekt av den farmasøytisk akseptable, polymere matriks.
NO20071853A 2004-09-17 2007-04-11 Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose. NO20071853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409874A FR2875409B1 (fr) 2004-09-17 2004-09-17 Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
PCT/FR2005/002288 WO2006032762A2 (fr) 2004-09-17 2005-09-15 Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose

Publications (1)

Publication Number Publication Date
NO20071853L true NO20071853L (no) 2007-06-15

Family

ID=34948358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071853A NO20071853L (no) 2004-09-17 2007-04-11 Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.

Country Status (17)

Country Link
US (1) US9084730B2 (no)
EP (1) EP1791524B1 (no)
JP (1) JP5224812B2 (no)
KR (1) KR101342193B1 (no)
CN (2) CN102247601A (no)
AU (1) AU2005286396B2 (no)
BR (1) BRPI0515390A (no)
CA (1) CA2579673C (no)
EA (1) EA012850B1 (no)
FR (1) FR2875409B1 (no)
IL (1) IL181773A0 (no)
MA (1) MA28858B1 (no)
MX (1) MX2007003162A (no)
NO (1) NO20071853L (no)
NZ (1) NZ553780A (no)
WO (1) WO2006032762A2 (no)
ZA (1) ZA200702214B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
BRPI0707584A2 (pt) * 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
JP2011518785A (ja) 2008-04-17 2011-06-30 サノフイ−アベンテイス 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
CN102078307B (zh) * 2009-12-01 2012-11-07 天津市汉康医药生物技术有限公司 一种盐酸决奈达隆固体分散体的药物组合物及其制备方法
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
WO2011135582A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
WO2011135581A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
JP2013526572A (ja) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
WO2012001673A1 (en) * 2010-06-28 2012-01-05 Mapi Pharma Holdings (Cyprus) Limited Amorphous form of dronedarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
JP2013535516A (ja) 2010-08-17 2013-09-12 ルピン・リミテッド ドロネダロンの制御放出製剤
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US9204667B2 (en) * 2010-12-01 2015-12-08 R.J. Reynolds Tobacco Company Smokeless tobacco pastille and injection molding process for forming smokeless tobacco products
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
US20150017242A1 (en) 2012-02-20 2015-01-15 Lupin Limited Bilayer Tablet of Dronedarone
CN103054820B (zh) * 2012-08-22 2016-07-13 石药集团中奇制药技术（石家庄）有限公司 一种盐酸决奈达隆药物组合物及其制备方法
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
RU2019109633A (ru) 2016-09-09 2020-10-09 Мерк Патент Гмбх Способ изготовления твердой фармацевтической лекарственной формы
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
DE19938672C2 (de) * 1999-08-06 2001-11-22 Biop Biopolymer Gmbh Verfahren zur Herstellung einer thermoplastischen Polymermischung auf Stärkebasis durch reaktive Extrusion
WO2003000294A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical

Also Published As

Publication number Publication date
EP1791524A2 (fr) 2007-06-06
EA200700658A1 (ru) 2007-08-31
KR101342193B1 (ko) 2013-12-16
AU2005286396A1 (en) 2006-03-30
CA2579673A1 (fr) 2006-03-30
JP5224812B2 (ja) 2013-07-03
CN102247601A (zh) 2011-11-23
CN101039657A (zh) 2007-09-19
EA012850B1 (ru) 2009-12-30
FR2875409A1 (fr) 2006-03-24
WO2006032762A2 (fr) 2006-03-30
JP2008513421A (ja) 2008-05-01
BRPI0515390A (pt) 2008-07-22
CN101039657B (zh) 2012-07-18
MA28858B1 (fr) 2007-09-03
EP1791524B1 (fr) 2014-11-19
MX2007003162A (es) 2007-05-16
US9084730B2 (en) 2015-07-21
NZ553780A (en) 2010-08-27
KR20070055601A (ko) 2007-05-30
HK1111608A1 (en) 2008-08-15
WO2006032762A3 (fr) 2006-06-01
CA2579673C (fr) 2014-11-18
ZA200702214B (en) 2008-09-25
US20070243257A1 (en) 2007-10-18
FR2875409B1 (fr) 2010-05-07
IL181773A0 (en) 2007-07-04
AU2005286396B2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
NO20071853L (no) Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose.
Sinha et al. Colonic drug delivery of 5-fluorouracil: an in vitro evaluation
RU2004137118A (ru) Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления
NO20080357L (no) Farmasoytiske sammensetninger for modifisert avgivelse, samt fremgangsmater for fremstilling av samme
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
WO2003064404A1 (en) 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
WO2004108162A3 (en) Controlled release pharmaceutical composition
NO20062798L (no) Anvendelse av en vannholdig dispersjon av i det minste en bio-nedbrytbar polymer inneholdende i det minste et stabiliseringsmiddel for fremstilling av en vanndig filmdannende sammensetning
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
DE602005025083D1 (no)
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
BRPI0410219A (pt) composições farmacêuticas de vareniclina
SE0402762D0 (sv) Indazole sulphonamide derivatives
BR0307278A (pt) Formulação oral de liberação imediata, e, método para preparar uma formulação
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2007120930A3 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
ATE493134T1 (de) Gefriergetrocknetes präparat mit methylcobalamin und verfahren zu seiner herstellung
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions
WO2007052307A3 (en) Stable solid oral dosage forms of valsartan
NO20032581L (no) Farmasöytisk formulering av gepiron for oral administrering
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
ATE361080T1 (de) Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application